Roles of Nrf2 in Gastric Cancer: Targeting for Therapeutic Strategies
Tahereh Farkhondeh,
Ali Mohammad Pourbagher-Shahri,
Mohsen Azimi-Nezhad,
Fatemeh Forouzanfar,
Aranka Brockmueller,
Milad Ashrafizadeh,
Marjan Talebi,
Mehdi Shakibaei,
Saeed Samarghandian
Affiliations
Tahereh Farkhondeh
Cardiovascular Diseases Research Center, Birjand University of Medical Sciences, Birjand 9717853577, Iran
Ali Mohammad Pourbagher-Shahri
Faculty of Medicine, Birjand University of Medical Sciences, Birjand 9717853577, Iran
Mohsen Azimi-Nezhad
Noncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur 9318614139, Iran
Fatemeh Forouzanfar
Medical Toxicology Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad 9177948564, Iran
Aranka Brockmueller
Musculoskeletal Research Group and Tumor Biology, Chair of Vegetative Anatomy, Institute of Anatomy, Faculty of Medicine, Ludwig-Maximilian-University Munich, Pettenkoferstrasse 11, D-80336 Munich, Germany
Milad Ashrafizadeh
Faculty of Engineering and Natural Sciences, Sabanci University, Orta Mahalle, Üniversite Caddesi No. 27, Orhanlı, Tuzla, Istanbul 34956, Turkey
Marjan Talebi
Department of Pharmacognosy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran 1996835113, Iran
Mehdi Shakibaei
Musculoskeletal Research Group and Tumor Biology, Chair of Vegetative Anatomy, Institute of Anatomy, Faculty of Medicine, Ludwig-Maximilian-University Munich, Pettenkoferstrasse 11, D-80336 Munich, Germany
Saeed Samarghandian
Noncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur 9318614139, Iran
Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) is a specific transcription factor with potent effects on the regulation of antioxidant gene expression that modulates cell hemostasis under various conditions in tissues. However, the effects of Nrf2 on gastric cancer (GC) are not fully elucidated and understood. Evidence suggests that uncontrolled Nrf2 expression and activation has been observed more frequently in malignant tumors, including GC cells, which is then associated with increased antioxidant capacity, chemoresistance, and poor clinical prognosis. Moreover, Nrf2 inhibitors and the associated modulation of tumor cell redox balance have shown that Nrf2 also has beneficial effects on the therapy of various cancers, including GC. Based on previous findings on the important role of Nrf2 in GC therapy, it is of great interest to scientists in basic and clinical tumor research that Nrf2 can be active as both an oncogene and a tumor suppressor depending on different background situations.